IWM vs XBI
iShares Russell 2000 ETF vs SPDR S&P Biotech ETF
- • IWM has the lower expense ratio at 0.19% vs 0.35% for XBI.
- • IWM pays a higher dividend yield (0.88%).
Side-by-side metrics
| Metric | IWM | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.19% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.88% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $82.97B | $10.73B |
YTD return | 19.72% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.26 | 1.10 |
P/E ratio | 18.44 | — |
Last price | $297.64 | $164.01 |
Inception | — | — |
Issuer | iShares | State Street |
IWM top holdings
| MOG-A | Moog Inc Class A | 0.38% |
| HUT | Hut 8 Corp | 0.37% |
| VSAT | Viasat Inc | 0.35% |
| BTSG | BrightSpring Health Services Inc | 0.35% |
| CYTK | Cytokinetics Inc | 0.35% |
| MXL | MaxLinear Inc | 0.34% |
| AGX | Argan Inc | 0.34% |
| UMBF | UMB Financial Corp | 0.33% |
| FROG | JFrog Ltd Ordinary Shares | 0.31% |
| RIOT | Riot Platforms Inc | 0.30% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About IWM
IWM (iShares Russell 2000 ETF) is US small-cap stocks (Russell 2000). Managed by iShares, the fund carries $83.0B in assets under management, an expense ratio of 0.19%, a dividend yield of 0.88%. Its largest holding is Moog Inc Class A (MOG-A), which represents 0.4% of the portfolio. Real Estate is the fund's largest sector exposure at 6.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.